Cinnarizine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Cinnarizine

Antivertigo Preparations

GB MHRA

Drug class: Antivertigo Preparations
Availability: See label
Markets covered: 1
Products on record: 6

Overview

Cinnarizine is an active pharmaceutical ingredient in the Antivertigo Preparations group (N07CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	6	May 15, 2026

GBUnited Kingdom· MHRA

6 products

Uses

GBOfficial regulatory label· revised February 20, 2026[1]

Treatment of vertigo symptoms of various origins. Cinnarizine/Dimenhydrinate Torrent 20mg/40mg Tablets are indicated in adults.

How to take

Sources & citations

[1]MHRA (UK) · PL366870460 · revised February 20, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised February 20, 2026[1]

The most frequently occurring ADRs are somnolence (including drowsiness, tiredness, fatigue, daze) occurring in about 8% of patients and dry mouth occurring in about 5% of patients in clinical trials. These reactions are usually mild and disappear within a few days even if treatment is continued.
The frequency of ADRs associated with Cinnarizine/Dimenhydrinate tablets in clinical trials and following spontaneous reports are included in the next table.
Tabulated list of adverse reactions:
Frequency of ADR Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare ≥1/10,000 to <1/1,000 Very rare <1/10,000 System organ class: Blood and lymphatic Leukopenia Thrombopenia system disorders Aplastic anaemia Immune system disorders Hypersensitivity reactions (eg cutaneo us reactions) Nervous system disorders Somnolence Headache Paraesthesia Amnesia Tinnitus Tremor Nervousness Convulsions Eye disorders Visual disorders Gastrointestinal disorders Dry mout h Abdominal pain Dyspepsia Nausea Diarrhoea Skin and subcutaneous tissue disorders Perspiration Rash Photosensitivity Renal and urinary disorders Urinary hesitancy In addition the following adverse reactions are associated with dimenhydrinate and cinnarizine (frequency cannot be estimated from the available data): Dimenhydrinate: paradoxical excitability (especially in children), worsening of an existing angle-closure glaucoma, reversible agranulocytosis.
Cinnarizine: constipation, weight gain, tightness of the chest, cholestatic jaundice, extrapyramidal symptoms, lupus-like skin reactions, lichen planus. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised February 20, 2026[1]

Cinnarizine/Dimenhydrinate tablets does not reduce blood pressure significantly, however, it should be used with caution in hypotensive patients. Cinnarizine/Dimenhydrinate tablets should be taken after meals to minimise any gastric irritation.
g. raised intraocular pressure, pyloro-duodenal obstruction, prostatic hypertrophy, hypertension, hyperthyroidism or severe coronary heart disease. Caution should be exercised when administering Cinnarizine/Dimenhydrinate tablets to patients with Parkinson’s disease.
Sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially “sodium-free”.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations